Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis Long-Term Debt Due in 2–3 Years by Year
Long-Term Debt Due in 2–3 Years ($M)
Novartis Long-Term Debt Due in 2–3 Years: $4,434M in FY2025, up 21.6% from a year earlier. That is the highest of the 9 years on record here.
Latest, FY2025
4,434
Period ended Dec 31, 2025
Change on a year earlier
+21.6%
3,645 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Note 19.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Long-Term Debt Due in 2–3 Years ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,434 | +21.6% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 3,645 | +449.8% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 663 | -79.8% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2022 | Dec 31, 2022 | 3,281 | +53.0% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2021 | Dec 31, 2021 | 2,144 | -15.8% | Novartis Form 20-F/A (0001370368-23-000048) ↗ |
| FY2020 | Dec 31, 2020 | 2,546 | -1.4% | Novartis Form 20-F (0001370368-22-000010) ↗ |
| FY2019 | Dec 31, 2019 | 2,583 | +22.4% | Novartis Form 20-F (0001370368-21-000006) ↗ |
| FY2018 | Dec 31, 2018 | 2,111 | +5.7% | Novartis Form 20-F (0001370368-20-000003) ↗ |
| FY2017 | Dec 31, 2017 | 1,997 | – | Novartis Form 20-F (0001370368-19-000002) ↗ |
Cite this data
StockData. (2026). Novartis Long-Term Debt Due in 2–3 Years ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/debt-maturity-2to3y
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.